4-(2-(5,6-dihydro-5,5-dimethyl-8-(2-phenylethynyl)naphthalen-2-yl)ethen-1-yl)benzoic acid,
BMS 204,493,
BMS 204493,
BMS 493,
BMS-204,493,
BMS-204493,
BMS204,493,
BMS204493,
BMS 493,
215030-90-3,
BMS-493,
BMS-204493,
BMS493,
CHEMBL472172,
4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid,
4-{(E)-2-[5,5-dimethyl-8-(phenylethynyl)-5,6-dihydronaphthalen-2-yl]ethenyl}benzoic acid,
GTPL2641,
SCHEMBL3690042,
SCHEMBL3690047,
CHEBI:132086,
BDBM50447840,
ZINC34023910,
AKOS024457650,
BMS204, 493,
NCGC00387103-01,
BMS 493, >=98% (HPLC),
RT-011577,
B7415,
J-014108,
(E)-4-[2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)naphthalen-2-yl]ethen-1-yl]benzoic acid,
4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(phenylethynyl)-2-naphthalenyl]ethenyl]-benzoic acid,
4-[(E)-2-[5,5-dimethyl-8-(2-phenylethynyl)-5,6-dihydronaphthalen-2-yl]ethenyl]benzoic acid,
EQO,
Epofolate,
Epothilone folate conjugate,
D0N2GC,
YCADIXLLWMXYKW-CMDGGOBGSA-N,
BMS204493,
BMS 204493,
BMS-753493,
BMS204,493,
CID9909190,
BMS 204,493,
BMS-204,493,
C542472,
BMS-748285 folate conjugate, Bristol-Myers Squibb,
4-{(E)-2-[5,5-Dimethyl-8-(phenylethynyl)-5,6-dihydro-2-napht,
Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS,
4-(2-(5,6-dihydro-5,5-dimethyl-8-(2-phenylethynyl)naphthalen-2-yl)ethen-1-yl)benzoic acid,
4-[(E)-2-[5,5-dimethyl-8-(2-phenylethynyl)-6H-naphthalen-2-yl]ethenyl]benzoic Acid,
Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb,
958646-17-8,